As reported by the American Journal of Nursing, among a group of fourteen to twenty-four year old females who were sexually active, the presence of HPV types 6, 11, 16, and 18 went from just over eighteen percent in the prevaccination years to only 2.1 percent between the years 2009 to 2012 (Halpern, 2016). With the presence of HPV types 6, 11, 16, and 18 dropping in a large amount over a couple of year period, evidence continues to show a positive benefit for teenage girls who have been vaccinated. Various trials have been conducted in the past by the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I, which observed young women between the ages of fifteen and twenty-six years, followed over a three-year period. In these trials, which consisted of over five-thousand women, the vaccine was discovered to have a ninety-eight percent effective rate in preventing all cervical lesions, which have been shown to lead to cervical cancers in women (Lonky, 2007). Likewise, when examining these benefits for young women ages seventeen to nineteen, studies have concluded that the vaccine seemed to be the most effective in younger girls and those who were not sexually active; meaning that, even if a person thinks they are not as risk for getting HPV, it can still be valuable for them to receive the
As reported by the American Journal of Nursing, among a group of fourteen to twenty-four year old females who were sexually active, the presence of HPV types 6, 11, 16, and 18 went from just over eighteen percent in the prevaccination years to only 2.1 percent between the years 2009 to 2012 (Halpern, 2016). With the presence of HPV types 6, 11, 16, and 18 dropping in a large amount over a couple of year period, evidence continues to show a positive benefit for teenage girls who have been vaccinated. Various trials have been conducted in the past by the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I, which observed young women between the ages of fifteen and twenty-six years, followed over a three-year period. In these trials, which consisted of over five-thousand women, the vaccine was discovered to have a ninety-eight percent effective rate in preventing all cervical lesions, which have been shown to lead to cervical cancers in women (Lonky, 2007). Likewise, when examining these benefits for young women ages seventeen to nineteen, studies have concluded that the vaccine seemed to be the most effective in younger girls and those who were not sexually active; meaning that, even if a person thinks they are not as risk for getting HPV, it can still be valuable for them to receive the